Figure 1 | Signal Transduction and Targeted Therapy

Figure 1

From: Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Figure 1

Preparation and characterization of T-SA1 and T-SA2. (a) Schematic diagram of T-SA1 and T-SA2 containing anti-HER2 scFv, the linkers and HSA. (b) SDS-PAGE analysis of purified T-SA1 and T-SA2. T-SA1 and T-SA2 loaded with reducing (R) and non-reducing loading buffer (N) were separated on a 10% polyacrylamide gel. Marker: PageRuler PlusPrestained-Protein Ladder. (c) Binding activity analysis of T-SA1 and T-SA2 in HER2-negative and -positive cells by flow cytometry. The results indicated that T-SA1 and T-SA2 could specifically bind to HER2-positive cells. Blue violet: control group; green: anti-HER2 monoclonal antibody trastuzumab; pink: T-SA1; blue: T-SA2.

Back to article page